Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
SPINK1 as a plasma marker for tumor hypoxia and a therapeutic target for radiosensitization
Tatsuya Suwa, … , Ester M. Hammond, Hiroshi Harada
Tatsuya Suwa, … , Ester M. Hammond, Hiroshi Harada
Published November 8, 2021
Citation Information: JCI Insight. 2021;6(21):e148135. https://doi.org/10.1172/jci.insight.148135.
View: Text | PDF
Research Article Cell biology Oncology

SPINK1 as a plasma marker for tumor hypoxia and a therapeutic target for radiosensitization

  • Text
  • PDF
Abstract

Hypoxia is associated with tumor radioresistance; therefore, a predictive marker for tumor hypoxia and a rational target to overcome it have been sought to realize personalized radiotherapy. Here, we show that serine protease inhibitor Kazal type I (SPINK1) meets these 2 criteria. SPINK1 expression was induced upon hypoxia (O2 < 0.1%) at the transcription initiation level in a HIF-dependent manner, causing an increase in secreted SPINK1 levels. SPINK1 proteins were detected both within and around hypoxic regions of xenografted and clinical tumor tissues, and their plasma levels increased in response to decreased oxygen supply to xenografts. Secreted SPINK1 proteins enhanced radioresistance of cancer cells even under normoxic conditions in EGFR-dependent and nuclear factor erythroid 2–related factor 2–dependent (Nrf2-dependent) manners and accelerated tumor growth after radiotherapy. An anti-SPINK1 neutralizing antibody exhibited a radiosensitizing effect. These results suggest that SPINK1 secreted from hypoxic cells protects the surrounding and relatively oxygenated cancer cells from radiation in a paracrine manner, justifying the use of SPINK1 as a target for radiosensitization and a plasma marker for predicting tumor hypoxia.

Authors

Tatsuya Suwa, Minoru Kobayashi, Yukari Shirai, Jin-Min Nam, Yoshiaki Tabuchi, Norihiko Takeda, Shusuke Akamatsu, Osamu Ogawa, Takashi Mizowaki, Ester M. Hammond, Hiroshi Harada

×

Figure 3

SPINK1 secreted from cells induces cancer radioresistance in a paracrine manner.

Options: View larger image (or click on image) Download as PowerPoint
SPINK1 secreted from cells induces cancer radioresistance in a paracrine...
(A) HeLa tumor xenografts were stained with antibodies against a hypoxia marker, pimonidazole (green), or SPINK1 (red). Blue, counter staining with Hoechst 33342. The dotted line represents the outside edge of the pimonidazole-positive regions. Scale bar: 50 μm. (B–E) After 24 hours serum starvation, DU145 cells were precultured in the presence or absence of 100 ng/mL rSPINK1 for 24 hours, treated with the indicated dose of γ-ray irradiation, and subjected to the clonogenic survival assay (B), colorimetric cell viability assay (C), and FACS analysis for the cell cycle status (D) and sub-G1 fraction (E). The cells were precultured and irradiated under the indicated oxygen conditions in C. (F and G) After transfection with either pcDNA4/SPINK1 (SPINK1) or its EV, the indicated cells were precultured under mild hypoxic conditions (O2 = 3%) for 48 hours, treated with the indicated dose of γ-ray irradiation under the same oxygen conditions as the preculture, and subjected to the clonogenic survival assay. (H–K) The indicated cells were transfected with either pcDNA4/SPINK1-ΔSP (SPINK1-ΔSP) or its EV and cultured for 48 hours. Then, both the culture media and cell lysates were subjected to Western blotting using the indicated antibodies (H and J), and then, cells were irradiated with the indicated doses of γ-rays and subjected to the clonogenic survival assay (I and K). The exogenously expressed SPINK1-ΔSP was detected using anti-myc tag Ab (H and J). (L) After 24 hours serum starvation, DU145 cells were treated with or without 100 ng/mL rSPINK1 in combination with SPINK1-neutralizing antibody or control IgG (0.5 μg/mL) for 24 hours and subjected to the colorimetric cell viability assay. Data are represented as mean ± SD (n = 3 in C–E and L, and n = 6 in B, F, G, I, and K). Student’s t test. *P < 0.05, **P < 0.01. SPINK1, serine peptidase inhibitor Kazal type 1; EV, empty vector.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts